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Objectives To prospectively evaluate the effect of different dietary management strategies on the rate of acqui-
sition of tolerance in children with cow’s milk allergy (CMA).
Study designOtherwise healthy children (aged 1-12months) diagnosedwith CMAwere prospectively evaluated.
The study population was divided into 5 groups based upon the formula used for management: (1) extensively
hydrolyzed casein formula ([EHCF], n = 55); (2) EHCF + Lactobacillus rhamnosus GG [LGG], n = 71); (3) hydrolyzed
rice formula (RHF, n = 46); (4) soy formula (n = 55); and (5) amino acid based formula (n = 33). A food challenge was
performed after 12 months to assess acquisition of tolerance.
Results Two hundred sixty children were evaluated (167 male, 64.2%; age 5.92 months, 95% CI 5.48-6.37; body
weight 6.66 kg, 95% CI 6.41-6.91; IgE-mediated CMA 111, 42.7%). The rate of children acquiring oral tolerance
after 12 months was significantly higher (P < .05) in the groups receiving EHCF (43.6%) or EHCF + LGG (78.9%)
compared with the other groups: RHF (32.6%), soy formula (23.6%), and amino acid based formula (18.2%). Binary
regression analysis coefficient (B) revealed that the rate of patients acquiring tolerance at the end of the study was
influenced by 2 factors: (1) IgE-mediated mechanism (B 2.05, OR 0.12, 95% CI 0.06-0.26; P < .001); and (2) for-
mula choice, such that those receiving either EHCF (B 1.48, OR 4.41, 95% CI 1.44-13.48; P = .009) or EHCF + LGG
(B 3.35, OR 28.62, 95% CI 8.72-93.93; P < .001).
Conclusions EHCF accelerates tolerance acquisition in children with CMA if compared with other dietetic
choices. This effect is augmented by LGG. (J Pediatr 2013;163:771-7).See editorial, p 620ow’s milk allergy (CMA) is the most common food allergy in early childhood, with an estimated incidence rangingCbetween 2% and 3%.1,2 The long-term prognosis for the majority of affected infants generally is good, with80%-90% naturally acquiring tolerance to cow milk proteins (CMP) by the age of 5 years.3 However, recent studies
suggest that the natural history of CMA is changing, with an increasing persistence until later ages,4,5 and increasing severity
of illness.1,3
Recent guidelines addressing the optimal therapeutic approach for children with CMA recommend the use of substitutive
formulas.6,7 However, these recommendations are based largely on the safety, nutritional value, and relative costs of these
formulas. The potential impact of different hypoallergenic formulas on disease duration in children with CMA are not
considered due to a lack of comparative data.
We have demonstrated that the addition of the probiotic Lactobacillus rhamnosus GG, (LGG) to an extensively hydrolyzed
casein formula (EHCF) accelerates acquisition of tolerance in infants with CMA compared with patients receiving EHCF
alone.8 To investigate whether a similar benefit is observed comparing EHCF containing LGG with other formulas, we designed
a study to prospectively evaluate the effect of various dietetic choices on acquisition of tolerance after 12 months in children
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AAF Amino acid based formula
APT Atopy patch testing
B Binary regression analysis
coefficient
CM Cow milk
CMA Cow’s milk allergy
CMP Cow milk proteins
DBPCFC Double-blind placebo-controlled
food challenge
EHCF Extensively hydrolyzed casein
formula
LGG Lactobacillus rhamnosus GG
RHF Hydrolyzed rice formula
SF Soy formula
SPT Skin prick testing
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This open nonrandomized trial was conducted from July 1,
2010-June 30, 2012. We prospectively evaluated otherwise
healthy infants (1-12 months of age at the diagnosis) referred
to 3 tertiary care pediatric allergy centers for a diagnostic oral
food challenge for suspected CMA. All subjects were in stable
clinical condition without symptoms of CMA, and already
treated for a period of 15-30 days prior to recruitment with
a formula that was selected and prescribed by a family pedi-
atrician or physician when the symptoms appeared. Manage-
ment following study entry did not vary depending upon
formula type. Patients who used pre-probiotic products in
the last 4 weeks, and patients with CMP-induced anaphy-
laxis, eosinophilic disorders of the gastrointestinal tract,
food protein-induced enterocolitic syndrome, concomitant
chronic systemic diseases, congenital cardiac defects, active
tuberculosis, autoimmune diseases, immunodeficiency,
chronic inflammatory bowel diseases, celiac disease, cystic
fibrosis, metabolic diseases, lactose intolerance, malignancy,
chronic pulmonary diseases, and malformations of the
gastrointestinal tract were excluded.
At the first visit (visit 1), we performed: (1) full anamnestic
and clinical evaluation; (2) skin prick testing (SPT) and atopy
patch testing (APT); and (3) oral food challenge to confirm
the diagnosis of CMA. Patients with a certain diagnosis of
food allergy based upon the result of oral food challenge
were enrolled and continued on an exclusion diet using the
same formula prescribed by the referring physician for the
treatment of CMA. We planned a new full clinical evaluation
after 6 months (visit 2), and again after 12 months (visit 3),
including all of the tests performed at visit 1 to evaluate
whether the subjects had achieved oral tolerance to CMP.
Demographic and clinical characteristics were also obtained
in each subject. The study was approved by the Ethics Com-
mittee of the University of Naples, Federico II. The clinical
evaluation and study protocols were identical in each study
center.
SPT was performed using fresh cow milk (CM) containing
3.5% fat applied to the patient’s volar forearm, and a 1-mm
single peak lancet (ALK, Copenhagen, Denmark), with hista-
mine dihydrochloride (10 mg/mL) and isotonic saline
solution (sodium chloride 0.9%) as positive and negative
control, respectively. Reactions were recorded on the basis
of the largest diameter (in mm) of the wheal and flare at 15
minutes. The SPT result was considered “positive” if thewheal
was 3 mm or larger, without reaction of the negative control.
APT was performed as previously described.9 Briefly, 1
drop (50 mL) of fresh CM containing 3.5% fat was placed
on filter paper and applied with adhesive tape to the unaf-
fected skin of the child’s back, using 12-mm aluminium
cups (Finn Chambers On-Scan Pore; Epitest Ltd Oy,
Tuusula, Finland). Isotonic saline solution was the negative
control. The occlusion time was 48 hours and results were
read 20 minutes and 24 hours after removal of the cups. To
exclude false positive reactions, we also tested allergens in772a 1:10 solution. Seventy-two hours after the start of the
test, reactions were classified as follows:  negative; +/
doubtful: erythema only; + weakly positive: erythema and
slight infiltration; ++ strongly positive: erythema, infiltra-
tion, papules; +++ very strongly positive: erythema, infiltra-
tion, papules, vesicles. Infants and their families were
requested to report any delayed skin reaction that was no-
ticed after this time. Irritant or doubtful reactions, including
sharply demarcated confluent erythema, or reactions con-
fined to margins without infiltration, were deemed negative.
All food challenges were performed in a double-blind pla-
cebo-controlled food challenge (DBPCFC) manner, and took
place in the outpatient clinic of the centers involved in the
study, on 2 separate days with a 1-week interval. Parents of
infants taking antihistamine were advised to withhold these
medications for 72 hours before and during the challenge. Ran-
domization and preparation of the challenges were performed
by experienced food allergy dieticians not directly involved in
the procedures. Briefly, every 20 minutes, successive doses
(0.1, 0.3, 1, 3, 10, 30, and 100 mL) of fresh pasteurized CM
containing 3.5% fat or an amino acid-based formula (AAF)
were administered. Full emergency equipment and medica-
tions (epinephrine, antihistamines, and steroids) were avail-
able. In each center, the results were assessed simultaneously
by 3 experienced pediatric allergists. Study subjects were scored
for 9 items divided into 4main categories: (1) general (lowered
blood pressure plus tachycardia); (2) skin (rash, urticaria/an-
gioedema); (3) gastrointestinal (nausea/repeated vomiting,
crampy-like abdominal pain, diarrhea); and (4) respiratory
(sneezing/itching, nasal congestion/rhinorrhea, stridor deriv-
ing from upper airway obstruction or wheezing) on a 0- to
3-point scale (0, none; 1, light; 2, moderate; and 3, severe). If
at least 2 of the 3 physicians independently scored any item at
level 3, or 2 (or more) items at level 2, the test result was con-
sidered positive. Clinical symptoms occurring within 2 hours
of administering the highest dose were defined as “immediate
reactions,” and those occurring more than 2 hours after the
highest dose were defined as “delayed reactions.” The infants
were observed for 2 hours after the final dose, and then dis-
charged. In the case of a positive DBPCFC, at any testing
dose, the patient remained under observation until symptom
resolution. If the patient did not show any symptoms within
the first 24 hours, parents were advised to give one single feed
of 100 mL of the tested formula (pasteurized CM with 3.5%
fat vs placebo) every day at home for 7 days. If any symptoms
occurredduring this period, the patients returned to the outpa-
tient clinic on the same day. After 7 days of administration, the
patients were examined and the parents interviewed at the cen-
ter. To rule out false-negative challenge result, parents were
asked to contact the center if any symptoms occurred in the
following 7 days after the DBPCFC procedures. The challenge
was considered negative if the patient tolerated the entire chal-
lenge, including the observation period. Clinical acquisition of
tolerance was defined by the presence of a negative DBPCFC.
Children with negative DBPCFC were reevaluated after 6
months to check the persistence of acquisition of tolerance.Berni Canani et al
Table. Baseline main demographic and clinical characteristics of the study population
Group 1 EHCF Group 2 EHCF + LGG Group 3 RHF Group 4 SF Group 5 AAF
N 55 71 46 55 33
Male, n (%) 41 (74.5) 38 (53.5) 28 (60.9) 37 (67.3) 23 (69.7)
Age, m (95% CI) 5.03 (4.20-5.86) 5.73 (4.83-6.62) 6.65 (5.53-7.76) 6.45 (5.45-7.45) 5.93 (4.57-7.30)
Weight, kg (95% CI) 6.47 (6.00-6.95) 6.66 (6.14-7.18) 6.97 (6.36-7.58) 6.96 (6.41-7.51) 6.04 (5.31-6.78)
Breastfeeding $2 months, n (%) 41 (74.5) 54 (76.1) 38 (82.6) 38 (69.1) 24 (72.7)
IgE-mediated CMA, n (%) 24 (43.6) 27 (38) 23 (50) 23 (41.8) 14 (42.4)
Gastrointestinal symptoms, n (%) 35 (63.6) 51 (71.8) 30 (65.2) 31 (56.4) 25 (75.8)
Vomiting, n (%) 23 (41.8) 27 (38) 17 (37) 18 (32.7) 10 (30.3)
Diarrhea, n (%) 18 (32.7) 24 (33.8) 13 (28.3) 13 (23.6) 19 (57.6)
Cutaneous symptoms, n (%) 25 (45.5) 29 (40.8) 17 (37) 27 (49.1) 11 (33.3)
Atopic dermatitis, n (%) 21 (38.2) 26 (36.6) 15 (32.6) 21 (38.2) 9 (27.3)
Urticaria, n (%) 6 (10.9) 6 (8.5) 5 (10.9) 8 (14.5) 5 (15.2)
Respiratory symptoms, n (%) 6 (10.9) 7 (9.9) 6 (13) 7 (12.7) 3 (9.1)
September 2013 ORIGINAL ARTICLESThe primary end point was the rate of patients acquiring
clinical tolerance to CMP after 12 months of exclusion diet
with different formulas.
Statistical Analysis
The Kolmogorov–Smirnov test was used to determine
whether variables were normally distributed. For continu-
ous variables, groups were compared using the t test and
the Mann–Whitney U test. The c2 test and Fisher exact
test were used for categorical variables. Binary logistic
regression analysis was conducted to assess the possible
influence of the following variables on the primary out-
come: sex, age at randomization, breast-feeding, symp-
toms, IgE-mediated mechanism, and type of formula.
The level of significance for all statistical tests was
2-sided, P < .05. All analyses were conducted on an
intention-to-treat basis by a statistician blinded to patient
group assignment, using SPSS, v. 16.0 for Windows (SPSS
Inc, Chicago, Illinois).
Results
A total of 329 infants (aged <12 months) were referred to the
study centers for suspected CMA (Figure 1; available at
www.jpeds.com). Fourteen were excluded because of the
presence of at least 1 exclusion criteria and 55 were excluded
because of a negative DBPCFC. All of the subjects diagnosed
with CMA consented to participate in the study.
A total of 260 infants with CMA were subdivided in 5
groups depending on the formula they were receiving at
study entry: group 1 (EHCF, Nutramigen [Mead Johnson,
Rome, Italy], n = 52 and Nutriben hydrolyzed [Nutriben,
Milan, Italy], n = 3); group 2 (EHCF + LGG, Nutramigen
LGG [Mead Johnson], n = 71); group 3, (hydrolyzed rice
formula [RHF], Risolac [Plasmon, Milan, Italy], n = 46);
group 4, (soy formula [SF, Isomil [Abbott, Milan, Italy]],
n = 23; Sinelac [Humana, Milan, Italy], n = 18 and
Nutrilon Soya [Nutricia, Milan, Italy], n = 14); group 5,
(AAF, Neocate [Nutricia], n = 16; Nutramigen AA
[Mead Johnson], n = 9; and Sineall [Humana], n = 8).
Seven patients were lost to follow-up (group 1, n = 2;
group 2, n = 3; group 3 = 0; group 4, n = 1; group 5,Formula Selection for Management of Children with Cow’s Milk A
Tolerance: A Prospective Multicenter Studyn = 1). Demographic and clinical characteristics of all 5
groups at baseline were similar (Table). The rate of
patients with CMA-related enterocolitis was similar in
the 5 study groups.
SPT and APT Results
Skin prick tests were performed in all study subjects at base-
line (visit 1), andwere repeated after 12months (visit 2) in in-
fants presenting with IgE-mediated CMA. At visit 1, 96
subjects showed positive SPT. The median wheal size (IQR)
was similar in the 5 groups: group 1, 8.5 mm (3.0); group 2,
7 mm (4.7); group 3, 6 mm (4.0); group 4, 6 mm (4.0); group
5, 7mm(3.0). At visit 2, the total number of patients with pos-
itive SPT tended to decrease in all groups except in group 5.
The difference was significant only in group 2 (Figure 2, A).
Similarly, APTs were performed in all patients at baseline
(visit 1) and after 12 months at visit 3 in infants with non-
IgE-mediated CMA. At visit 1, 97 subjects showed positive
APT and no differences were observed among groups
regarding the number of patients with positive APT and
severity of skin signs. At visit 2, the number of children with
positive APT decreased in all groups except in group 5, but
the difference was significant only in group 1 and group 2
(Figure 2, B).
Development of Tolerance
Figure 3 shows the rate of acquisition of full tolerance after
12 months of an exclusion diet in each group. At 12
months, group 1 and group 2 demonstrated higher rates of
CM tolerance compared with other groups. Patients with
negative DBPCFC at 12 months were able to consume at
least 1 full cup daily of CM without signs and symptoms
related to CMA in the following 6 months.
All reactions induced by the DBPCFC were assessed by the
physicians involved in the study. No placebo reactions were
observed among all challenges. The vast majority of patients
with IgE-mediated CMA reacted to the first 4 doses without
differences among groups. No adverse events were observed
during the study.
All patients with non-IgE-mediated CMA who presented
with a positive challenge reactedwithin 48 hours after the pro-
cedure, without differences among groups. Figure 4 showsllergy Influences the Rate of Acquisition of 773
Figure 2. Results of allergy screening test during the study. A, SPT in children with IgE-mediated CMA. B, APT in children with
non-IgE-mediated CMA.
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subdivided according to the CMA mechanism. Binary
regression analysis coefficient (B) revealed that the rate of
acquisition of tolerance at the end of the study was
influenced by the mechanism of CMA (ie, being lower in
subjects with an IgE-mediated mechanism [B 2.05, OR
0.12, 95% CI 0.06-0.26; P < .001]) and by formula type,
being increased with use of EHCF (B 1.48, OR 4.41, 95% CI7741.44-13.48; P .009) and EHCF + LGG (B 3.35, OR 28.62,
95% CI 8.72-93.93; P < .001).
Discussion
Our results show that the selection of a particular type of for-
mula influences the rate of acquisition of tolerance in chil-
dren with CMA. Our main finding is that children affectedBerni Canani et al
Figure 3. Rate of patients acquiring tolerance to oral food challenge after 12 months of exclusion diet with different formulas.
September 2013 ORIGINAL ARTICLESby CMA who receive EHCF alone or in combination with
LGG, for the dietary management of their condition, achieve
tolerance at 12 months significantly more frequently than
their peers who receive RHF, SF, or AAF.
Subgroup analysis showed that among subjects with
IgE-mediated or with non-IgE-mediated CMA, only those
receiving EHCF containing LGG achieved tolerance more
frequently than those receiving other formulas. A positive
trend in the rate of patients acquiring tolerance at the end
of the study period was observed for children receiving
EHCF alone compared with children receiving RHF, SF, or
AAF. The results could be explained at least in part by the
number of patients enrolled in the different groups resulting
in a lower power to detect differences. However, these results
are consistent with our previous data showing that in both
IgE- and non-IgE-mediated CMA, the addition of LGG to
EHCF resulted in a higher rate of acquisition of tolerance
after 12 months of treatment.8
Two other studies have addressed the possible influence of
the choice of different formulas on the rate of acquisition of
tolerance in patients with CMA. The first study showed no
differences in acquisition of tolerance at 12 months in chil-
dren with IgE-mediated CMA receiving a partially hydro-
lyzed rice protein formula supplemented with lysine and
threonine compared with those receiving an extensively hy-
drolyzed CMP formula (containing casein, 40%; and whey
proteins, 60%).10 The second study compared SF, extensively
hydrolyzed CMP (casein or whey proteins) formulas, and
RHF in children with IgE-mediated CMA.11 This study in-
cluded subjects treated with both an EHCF and an extensively
hydrolyzed whey proteins formula in the same group and had
small numbers of patients in each group. Despite these limi-
tations, this study also found no differences between formulaFormula Selection for Management of Children with Cow’s Milk A
Tolerance: A Prospective Multicenter Studygroups in the rate of acquisition of tolerance to CMP after 12
months. These data are in agreement with our findings that
in infants with IgE-mediated CMA, management with
EHCF does not result in a significantly higher rate of acqui-
sition of tolerance rate at 12 months compared with a RHF,
but all studies to date are relatively small and a difference may
be detectable with a larger sample size.
Patients exposed to CM residues achieve oral tolerance
earlier than patients who follow different dietary regimens;
this may be due to a specific immunomodulatory effect in-
duced by hydrolyzed casein peptides, as suggested by animal
model.12,13 These small peptides are absent in the other for-
mulas evaluated in our study. There are also clinical data in-
dicating that EHCF is able to prevent allergic manifestations
in at-risk children.14 LGG compared with EHCF alone has
been shown to more effectively attenuate the increased intes-
tinal permeability observed in infants with food allergy, and
to decrease fecal calprotectin and the persistence of occult
fecal blood losses at 1 month in infants with CMA.15,16 Ad-
ministration of LGG is associated with a complex response
in intestinal mucosa, reflected by the up- and down-
regulation of several genes involved in the immune response,
inflammation, cell–cell signaling, signal transcription, and
transduction.17 LGG is known to modulate immune func-
tions via various pathways, including those involving enter-
ocytes, monocytes, mast cells, dendritic cells, and regulatory
T lymphocytes.18-21 LGG alters the generation of cytokines
that may be involved in IgE- or non-IgE-mediated CMA
(ie, interleukin-4, interleukin-5, interleukin-10, interferon-
g, transforming growth factor-b, tumor necrosis factor-a)
and, thereby, can positively modulate the major pathways in-
volved in CMA pathogenesis.18–22 It is important to recog-
nize that these results cannot be generalized to otherllergy Influences the Rate of Acquisition of 775
Figure 4. Rate of patients acquiring tolerance after 12 months of exclusion diet with different formulas in the 5 study groups
subdivided according to the CMA mechanism. A, IgE-mediated CMA. B, Non-IgE-mediated CMA.
THE JOURNAL OF PEDIATRICS  www.jpeds.com Vol. 163, No. 3probiotics or other Lactobacillus strains. Other Lactobacillus
strains have different modes of action and varied effective-
ness in model immune cell systems.22 The differences
between Lactobacillus strains is further demonstrated by
comparative genomics studies that reveal that strain GG
contains 331 strain-specific proteins.23 Finally, it has been
recently demonstrated that daily supplements of LGG
resulted in a dramatic shift in the composition of the intesti-
nal microbial community with a large increase in the number
of taxa previously associated with a decreased risk for the
development of allergy and atopy.24776The main limitations of our study are related to the lack of
randomization and the lack of patient groups treated with
other potentially available dietary strategies for the manage-
ment of CMA (ie, extensively hydrolyzed whey formula, or
extensively hydrolyzed SF). This was necessary because of
the difficulties in recruitment of patients with CMA prior
to treatment initiated by the primary care physician. Patients
were first evaluated when referred for food challenge testing.
Randomization at this stage of management would further
complicate analysis. Therefore, formula selection was
determined by the initial managing physician and wasBerni Canani et al
September 2013 ORIGINAL ARTICLESpresumably based upon issues such as availability, taste,
different prices, and specific practice patterns that impact
choices of physicians.
Recent data suggest that the number of patients with per-
sistent CMA beyond infancy until later ages is increas-
ing.4,25,26 It is possible that this trend towards persistence
of CMA beyond infancy can be explained by changing pat-
terns of formula selection in infants with CMA with an in-
creased use of RHF, SF, or AAF. The most recent
European Society for Pediatric Gastroenterology, Hepatol-
ogy, and Nutrition (ESPGHAN) Clinical Guideline recom-
mends the initial administration of an extensively
hydrolyzed CMP formula in most infants with CMA because
it is well tolerated and less expensive.6 Our findings add fur-
ther data to support this recommendation because we ob-
served the earlier acquisition of tolerance to CMP.
Furthermore, our data suggest that administration of
EHCF with added LGG is more likely to lead to the develop-
ment of tolerance at an earlier age than other formulas. If this
finding is confirmed in other populations, the use of EHCF
with LGG may allow earlier normalization of the child’s diet
with resultant reduced impacts on their quality of life and
lower medical costs. n
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Figure 1. Numbers of participants throughout the study. IBD, inflammatory bowel disease; OFC, oral food challenge.
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